News | January 04, 2026
Elanco scores USDA nod for new canine allergy drug Befrena
Elanco expects Befrena to launch in the US in the first half of 2026
Elanco expects Befrena to launch in the US in the first half of 2026
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Patients with BRCA mutations often face aggressive disease and poor prognosis
Ryght AI tackles these hurdles with its AI Site Twin platform
Subscribe To Our Newsletter & Stay Updated
